Bellerophon Therapeutics will soon initiate a Phase 3 trial for its INOpulse inhaled nitric oxide therapy for the treatment of pulmonary hypertension associated with pulmonary fibrosis.
Bellerophon Therapeutics will soon initiate a Phase 3 trial for its INOpulse inhaled nitric oxide therapy for the treatment of pulmonary hypertension associated with pulmonary fibrosis.
Read More
Bellerophon Therapeutics has completed enrollment of its 159-patient Phase 2 clinical trial of INOpulse for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD).
Read More
